STEM-T enhanced TCR-T

About Immunova Therapeutics

Immunova Therapeutics is a private, preclinical-stage biotech developing a diversified portfolio of cancer immunotherapies, including engineered CAR-T and TCR-T cells, as well as novel vaccine and antibody platforms. The company's proprietary technologies, STEM-T and SAPNANO, aim to enhance T cell persistence and vaccine efficacy, respectively, addressing key challenges in solid tumors and treatment durability. Operating in the competitive but high-growth cell and gene therapy sector, Immunova is positioned to target both hematologic malignancies and solid tumors, though it faces significant technical, regulatory, and funding risks typical of early-stage biotechs.

Therapeutic Areas

Other Cancer (Solid Tumors) Drugs